

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

MAR 11 2004

Date: March 11, 2004

Page 1 of 1

Attorney Docket No.

Client Ref.

056291-5038

Applicant: CAMERON et al.

Appln. No.: 09/889,409

Filing Date: February 22, 2002

Examiner: Weddington, K.

Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
					Enclosed	No
	ER					
	FR					

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

W	GR	McClellan et al., "Candesartan Cilexetil A Review of its Use in Essential Hypertension", Drugs, 1998, pp. 847-869				
W	HR	Graham-Smith et al., "Oxford Handbook on Clinical Pharmacology and Pharmacotherapy", Moscow, "Meditsina" 2000, part 10 (Partial Translation)				
W	IR	Balabolkin, "Endocrinology", Moscow, "Universum Publishing" 1998, pp 427-430 and 420-421 (Partial Translation)				
W	JR	Small Medical Encyclopedia, Moscow, "Meditsina", 199 pp. 110 (Partial Translation)				
	KR					
	LR					
	MR					
	NR					
	OR					
	PR					

Examiner

Date Considered: 9-7-04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.